Evidence map›Paper›PMID 37779410›Full record

ArticleCurrent stem cell research & therapy2024

Adipose Mesenchymal Stem Cell-derived Exosomes Enhanced Glycolysis through the SIX1/HBO1 Pathway against Oxygen and Glucose Deprivation Injury in Human Umbilical Vein Endothelial Cells.

Xiangyu Zhang, Xin Zhang, Lu Chen, Jiaqi Zhao, Ashok Raj, Yanping Wang, Shulin Li, Chi Zhang, Jing Yang, Dong Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Current stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiangyu ZhangDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xin ZhangDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Lu ChenDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jiaqi ZhaoDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Ashok RajDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yanping WangDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shulin LiDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chi ZhangDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jing YangDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Dong SunDepartment of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xuzhou Medical College · CN

Funding

Jiangsu Provincial Commission of Health and Family Planning 2016103003, H201628Jiangsu Provincial Natural Science Foundation BK20211054National Natural Science Foundation of China 82270731, 82000703project of Jiangsu Provincial Post Graduate Innovation Plan KYCX17_1708, SJCX17_0560, KYCX18-2178, SJCX18_0715Science and technology development fund of Affiliated Hospital of Xuzhou Medical University XYFC2020001, XYFY2020038Suqian Natural Science Foundation K202101Xuzhou key R & D Program (Social Development) KC20160Xuzhou Medical leading Talent training Project XWRCHT20210038
6 · The paper itself

Abstract

backgroundAngiogenesis and energy metabolism mediated by adipose mesenchymal stem cell-derived exosomes (AMSC-exos) are promising therapeutics for vascular diseases.

objectivesThe current study aimed to explore whether AMSC-exos have therapeutic effects on oxygen and glucose deprivation (OGD) human umbilical vein endothelial cells (HUVECs) injury by modulating the SIX1/HBO1 signaling pathway to upregulate endothelial cells (E.C.s) glycolysis and angiogenesis.

methodsAMSC-exos were isolated and characterized following standard protocols. AMSC-exos cytoprotective effects were evaluated in the HUVECs-OGD model. The proliferation, migration, and tube formation abilities of HUVECs were assessed. The glycolysis level was evaluated by detecting lactate production and ATP synthesis. The expressions of HK2, PKM2, VEGF, HIF-1α, SIX1, and HBO1 were determined by western blotting, and finally, the SIX1 overexpression vector or small interfering RNA (siRNA) was transfected into HUVECs to assess the change in HBO1 expression.

resultsOur study revealed that AMSC-exos promotes E.C.s survival after OGD, reducing E.C.s apoptosis while strengthening E.C.'s angiogenic ability. AMSC-exos enhanced glycolysis and reduced OGD-induced ECs injury by modulation of the SIX1/HBO1 signaling pathway, which is a novel anti-endothelial cell injury role of AMSC-exos that regulates glycolysis

conclusionThe current study findings demonstrate a useful angiogenic therapeutic strategy for AMSC-exos treatment in vascular injury, thus providing new therapeutic ideas for treating ischaemic diseases.

Indexed as

ExosomesGlucoseGlycolysisHomeodomain ProteinsHuman Umbilical Vein Endothelial CellsMesenchymal Stem CellsSignal TransductionAdipose TissueApoptosisCell HypoxiaCell ProliferationHistone AcetyltransferasesHumansNeovascularization, PhysiologicOxygenGlucoseHistone AcetyltransferasesHomeodomain ProteinsKAT7 protein, humanOxygenSIX1 protein, humanAdipose mesenchymal stem cellendothelial cellsexosomeglucose.glycolysisoxygen

Identifiers

PMID37779410
OpenAlexW4387241806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.